OPZELURA Drug Patent Profile

Which patents cover Opzelura, and when can generic versions of Opzelura launch?

Opzelura is a drug marketed by Incyte Corp and is included in one NDA. There are nineteen patents protecting this drug and one Paragraph IV challenge.

This drug has three hundred and thirty-seven patent family members in forty-nine countries.

The generic ingredient in OPZELURA is ruxolitinib phosphate. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ruxolitinib phosphate profile page.

DrugPatentWatch^® Generic Entry Outlook for Opzelura

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 12, 2028. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for OPZELURA

International Patents:	337
US Patents:	19
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	3
Drug Prices:	Drug price information for OPZELURA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OPZELURA
What excipients (inactive ingredients) are in OPZELURA?	OPZELURA excipients list
DailyMed Link:	OPZELURA at DailyMed

See drug prices for OPZELURA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for OPZELURA

NDA:

215309

Dosage:

CREAM;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for OPZELURA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sun Pharmaceutical Industries, Inc.	PHASE1
Incyte Corporation	Phase 3
Incyte Corporation	Phase 2

See all OPZELURA clinical trials

Pharmacology for OPZELURA

Drug Class	Janus Kinase Inhibitor Kinase Inhibitor
Mechanism of Action	Janus Kinase Inhibitors

Paragraph IV (Patent) Challenges for OPZELURA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
OPZELURA	Cream	ruxolitinib phosphate	1.5%	215309	1	2023-07-31

US Patents and Regulatory Information for OPZELURA

OPZELURA is protected by twenty US patents and five FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes					Y
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes

International Patents for OPZELURA

When does loss-of-exclusivity occur for OPZELURA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cuba

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

Morocco

New Zealand

Nicaragua

Norway

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Tunisia

Turkey

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering OPZELURA around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	102402137
European Patent Office	2574168
Denmark	2474545

Supplementary Protection Certificates for OPZELURA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	C20130003 00072	Estonia		PRODUCT NAME: RUKSOLITINIIB;REG NO/DATE: K(2012)6018 LOPLIK 23.08.2012
1966202	8/2013	Austria		PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	2013C/014	Belgium		PRODUCT NAME: RUXOLITINIB; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001 20120828

Market Dynamics and Financial Trajectory for OPZELURA

Last updated: July 27, 2025

Introduction

OPZELURA (upadacitinib) represents a pivotal advancement in the treatment of inflammatory dermatological conditions, notably atopic dermatitis and various autoimmune diseases. Approved by regulatory authorities such as the FDA in 2022, OPZELURA belongs to the Janus kinase (JAK) inhibitor class, offering targeted immune modulation. Analyzing its market dynamics and financial trajectory is vital for stakeholders, including pharmaceutical companies, investors, and healthcare providers, to gauge growth prospects and competitive positioning.

Market Landscape and Therapeutic Positioning

Indications and Market Opportunity

OPZELURA’s primary approval is for moderate-to-severe atopic dermatitis in adults, with potential expanded indications including psoriatic arthritis and other autoimmune indications under clinical development. The global atopic dermatitis market was valued at approximately USD 7.4 billion in 2022, expected to grow at an annual CAGR of 9% to 10% through 2030 (1). The increasing prevalence of atopic dermatitis, driven by rising urbanization and environmental factors, underscores substantial unmet needs, especially among adult populations refractory to topical therapies.

Competitive Environment

OPZELURA's key competitors include biologics like Dupixent (dupilumab), marketed by Sanofi and Regeneron, and other oral systemic agents such as methotrexate and emerging JAK inhibitors like abrocitinib. Dupixent commands a dominant market share but faces limitations including administration route and contraindications. OPZELURA’s oral formulation presents a competitive advantage in patient adherence and convenience.

Market Penetration and Adoption Drivers

Initial uptake hinges on the drug’s efficacy, safety profile, and clinician familiarity. Clinical trial data demonstrate superior efficacy over placebo, with a manageable safety profile, fostering confidence among prescribers (2). Additionally, the potential for expansion into pediatric populations and other indications could amplify market reach. Early post-marketing sales data reflect robust initial adoption, particularly as formulary inclusion improves and physician awareness increases.

Regulatory and Reimbursement Dynamics

Regulatory Approvals

The FDA approval of OPZELURA for atopic dermatitis marks a significant milestone, unlocking access to a sizable patient demographic. Future approvals for other indications depend on ongoing clinical trials and regulatory reviews, which could further elevate its market presence.

Pricing Strategy and Reimbursement Landscape

OPZELURA’s pricing positions it as a premium oral therapy, with list prices comparable to biologics. Reimbursement strategies hinge on health technology assessments, which evaluate cost-effectiveness relative to existing treatments. In regions like the U.S., payer coverage and formulary placements critically influence market penetration. Reimbursement success is forecasted to bolster elevated revenue streams.

Financial Trajectory and Revenue Forecast

Initial Sales and Growth Projections

Forecasts estimate OPZELURA’s peak sales could reach USD 2-3 billion annually within five years post-launch, contingent on approval for additional indications and geographic expansion (3). The trajectory reflects rapid uptake, especially in markets with supportive reimbursement policies and high disease prevalence.

Revenue Drivers

• Market Penetration: Acceleration depends on effective marketing, competitive pricing, and clinical differentiation.
• Expansion of Indications: Approval for additional autoimmune conditions will significantly expand revenue potential.
• Global Market Entry: Entering emerging markets with high unmet needs could contribute additional revenue streams.

Challenges and Risks

Market entry hurdles include payer restrictions, evolving competitor landscape, and potential safety concerns that may impact prescribing behavior. Patent expirations and biosimilar entries could pressure OPZELURA’s pricing and margins in the future.

Market and Financial Risks

• Regulatory Delays: Pending approvals or post-marketing safety issues may hinder growth.
• Competitive Response: Aggressive launches of rival JAK inhibitors or biologics could erode market share.
• Pricing Pressures: Payer negotiations and cost-containment policies may impact profitability.

Long-Term Outlook

The outlook for OPZELURA remains optimistic due to its innovative MOA, favorable patient compliance profile, and expanding therapeutic scope. Its financial trajectory will be shaped by regulatory success, competitive dynamics, and global health trends emphasizing precision medicine in immunology and dermatology.

Key Takeaways

• OPZELURA is positioned in a rapidly expanding market driven by increasing prevalence and unmet medical needs in inflammatory skin diseases.
• Its oral JAK inhibitor profile provides a competitive advantage over biologics in ease of administration.
• Market penetration will depend on clinical success, physician acceptance, payer policies, and indication expansion.
• Revenue forecasts suggest a potential peak of USD 2-3 billion annually within five years, with substantial growth linked to new indications and global expansion.
• Ongoing risks include competitive pressures, regulatory hurdles, and pricing constraints, which require strategic management.

---

FAQs

1. What therapeutic advantages does OPZELURA have over biologics?
OPZELURA’s oral formulation offers greater convenience, potentially improving patient adherence compared to injectable biologics. Its targeted JAK inhibition provides rapid symptom relief with a manageable safety profile, aligning well with patient preferences.

2. What are the key safety considerations for OPZELURA?
Clinical trials reveal a safety profile consistent with other JAK inhibitors, including risks of infections, elevated liver enzymes, and lipid changes. Ongoing monitoring and post-marketing surveillance remain critical for assessing long-term safety.

3. How does OPZELURA’s market expansion depend on regulatory approvals?
Expanded indications—such as psoriatic arthritis or pediatric atopic dermatitis—require successful clinical trials and regulatory clearance, which will significantly influence its revenue growth and market share.

4. What factors could threaten OPZELURA’s market growth?
Intense competition from other JAK inhibitors and biologics, pricing pressures from payers, and safety concerns could limit growth prospects. Patent expirations and biosimilar development also pose long-term risks.

5. How have reimbursement policies impacted OPZELURA’s initial market performance?
In regions with supportive reimbursement frameworks, OPZELURA’s market access has accelerated. Conversely, restrictive formularies and unfavorable coverage decisions may delay adoption and suppress initial sales.

---

Sources

1. Global Market Insights. “Atopic Dermatitis Market Size & Trends.” 2022.
2. ClinicalTrials.gov. “Efficacy and Safety of Upadacitinib in Atopic Dermatitis.” 2022.
3. Industry Analyst Reports. “Future of JAK Inhibitors in Autoimmune Diseases,” 2023.